Literature DB >> 26908733

Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.

Mia Kontio1, Arto A Palmu2, Ritva K Syrjänen2, Mika Lahdenkari2, Esa Ruokokoski2, Irja Davidkin1, Outi Vaarala3, Merit Melin2.   

Abstract

BACKGROUND: Measles-mumps-rubella (MMR) vaccinations have been offered to Finnish children at 14-18 months and 6 years of age. In May 2011, the recommended age for the first vaccine dose was lowered to 12 months because of the European measles epidemic.
METHODS: Fingertip capillary blood samples were collected from 3-year-old Finnish children vaccinated once with MMR vaccine at 11-19 months of age. The immunoglobulin G (IgG) antibodies to all 3 MMR antigens were measured with enzyme-linked immunosorbent assay. Neutralizing antibodies and the avidity of antibodies were measured for measles virus.
RESULTS: From April through October 2013, 187 children were enrolled. Equally high proportions of the samples were seropositive for measles virus, mumps virus, or rubella virus antibodies, and there were no significant differences in the IgG antibody concentrations in children vaccinated at 11-13 months of age, compared with those vaccinated at 17-19 months of age. However, among children vaccinated at 11-13 months of age, boys had lower antibody concentrations than girls. Neutralizing measles virus antibody titers were above the threshold for protective immunity in all 78 samples analyzed. The measles virus antibody avidity indexes were high for all children.
CONCLUSIONS: MMR induces similar antibody responses in 12-month-old children as compared to 18-month-old children, but in boys increasing age appears to improve the antibody responses.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  MMR; antibody; immune response; immunization; measles; mumps; rubella; vaccination schedule; vaccine

Mesh:

Substances:

Year:  2016        PMID: 26908733     DOI: 10.1093/infdis/jiw058

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

1.  Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination.

Authors:  Emily A Voigt; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Beth R Larrabee; Daniel J Schaid; Gregory A Poland
Journal:  Vaccine       Date:  2016-08-30       Impact factor: 3.641

Review 2.  The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review.

Authors:  Stephanie L Hughes; Shelly Bolotin; Sumaiya Khan; Ye Li; Caitlin Johnson; Lindsay Friedman; Andrea C Tricco; Susan J M Hahné; Jane M Heffernan; Alya Dabbagh; David N Durrheim; Walter A Orenstein; William J Moss; Mark Jit; Natasha S Crowcroft
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

3.  Gender differences in measles incidence rates in a multi-year, pooled analysis, based on national data from seven high income countries.

Authors:  Manfred S Green; Naama Schwartz; Victoria Peer
Journal:  BMC Infect Dis       Date:  2022-04-11       Impact factor: 3.090

4.  Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis.

Authors:  Laura M Nic Lochlainn; Brechje de Gier; Nicoline van der Maas; Peter M Strebel; Tracey Goodman; Rob S van Binnendijk; Hester E de Melker; Susan J M Hahné
Journal:  Lancet Infect Dis       Date:  2019-09-20       Impact factor: 25.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.